In 2023 we welcomed further growth and research developments, broadening our reach and driving forward Icon’s research capabilities. Some notable achievements include:
We also welcomed a new Director of Research (Medical Oncology and Haematology), Dr Craig Gedye. Craig is an exceptional clinician and dedicated researcher with a wealth of knowledge and endless commitment to advances in cancer treatment. Craig’s contribution is already seeing growing research interest from Icon’s network of doctors, and he continues to work closely with our Director of Research (Radiation Medicine and Theranostics), A/Prof Jonathan Ramsay to move the dial on research opportunities.
As we reflect on last year’s achievements we set our sights on our future strategy with a truly global lens. In the next few years’ Icon’s research will continue to grow in Singapore, Australia and New Zealand and broaden into the United Kingdom and Malaysia. We will also open more trials and explore research opportunities in the field of Theranostics.
Together we’re contributing to improvements and outcomes in cancer treatment and beyond and bringing more hope and care to more people every day.
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into Singapore, Mainland China, Hong Kong and New Zealand.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.